Company: KROS
Filing Date: 2025-05-19
Form Type: DEFA14A
Source: 0001104659-25-050245
Chunk: 5

Company: Keros Therapeutics, Inc.
Filing Date: 2025-05-19
Form: DEFA14A
Chunk 5
---
 advances its pipeline
and determines the right path forward. The Keros Board will continue to make decisions that are in the best interests of its stockholders
to generate long-term value.

We urge you to vote in favor of each of Keros’ three
director nominees, Mary Ann Gray, Ph.D., Ran Nussbaum and Alpna Seth, Ph.D.

We thank you for your continued support.

Sincerely,

The Keros Board of Directors

| YOUR VOTE IS IMPORTANT, NO MATTER HOW MANY SHARES   
 YOU OWN.                                            
 YOU MAY VOTE BY TELEPHONE, THE INTERNET OR MAIL     
 BY FOLLOWING THE INSTRUCTIONS ON THE PROXY CARD.    
 WE URGE YOU TO VOTE TODAY!                          
 If you have any questions or require any assistance 
 with voting your shares, please contact:            
 7 Penn Plaza                                        
 New York, New York 10001                            
 Toll-Free: 1-800-322-2885                           
 Or                                                  
 Email:                                              
 proxy@MacKenziePartners.com                         |

Goldman Sachs & Co. LLC is serving as Keros’ financial advisor,
and Cooley LLP is serving as legal counsel.

About Keros Therapeutics, Inc.

Keros is a clinical-stage biopharmaceutical company focused on developing
and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of
the TGF-ß family of proteins. Keros is a leader in understanding the role of the TGF-ß family of proteins, which are master
regulators of the growth, repair and maintenance of a number of tissues, including blood, bone, skeletal muscle, adipose and heart tissue.
By leveraging this understanding, Keros has discovered and is developing protein therapeutics that have the potential to provide meaningful
and potentially disease-modifying benefit to patients. One of Keros’ product candidates, cibotercept (KER-012), is being developed
for the treatment of pulmonary arterial hypertension and for the treatment of cardiovascular disorders. Keros’ second product candidate,
KER-065, is being developed for the treatment of neuromuscular diseases. Keros’ most advanced product candidate, elritercept (KER-050),
is being developed for the treatment of cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndrome and
in patients with myelofibrosis.

Cautionary Note Regarding Forward-Looking Statements

Statements contained in this press release